Like other symptoms, itchy skin and rashes may not appear in the early stages of kidney disease. Instead, they may appear when the minerals in the blood become unbalanced due to the kidney’s ...

Acitretin: This medication is an oral (take by mouth) retinoid that can clear or markedly reduce widespread rashes, bumps, and other signs on your skin. Retinoids should not be used during pregnancy, ...

These rashes may develop due to changes in hormone levels, the rapid stretching of the skin, and underlying atopic (allergy-related) conditions. Some of these rashes can occur whether you are pregnant ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

If you've ever seen your skin turn colors after too much time spent next to a heating pad, space heater, or other heating element, you may have experienced a condition known as toasted skin syndrome.

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

Regeneron Pharmaceuticals on Monday presented positive Phase III data for its PD-1 inhibitor Libtayo, which yielded significant survival benefits when used as an adjuvant treatment for patients with ...